1. Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional study.
- Author
-
Buzibye, Allan, Wools-Kaloustian, Kara, Olagunju, Adeniyi, Twinomuhwezi, Ellon, Yiannoutsos, Constantin, Owen, Andrew, Neary, Megan, Matovu, Joshua, Banturaki, Grace, Castelnuovo, Barbara, Lamorde, Mohammed, Khoo, Saye, Waitt, Catriona, and Kiragga, Agnes
- Subjects
EFAVIRENZ ,HIV infections ,HIV-positive persons ,SEQUENCE analysis ,GENETIC mutation ,SINGLE nucleotide polymorphisms ,VIRAL load ,CROSS-sectional method ,BLOOD plasma ,BLOOD collection ,GENOTYPES ,PUERPERIUM ,DISEASE prevalence ,RESEARCH funding ,DRUG resistance in microorganisms ,STATISTICAL sampling ,WOMEN'S health ,PHENOTYPES - Abstract
Background: We investigated the association between CYP2B6 polymorphisms and efavirenz drug resistance among women living with HIV who started on antiretroviral therapy during pregnancy and with high viremia during post-partum. Methods: This was a cross-sectional study of women with viral loads greater than 1000 copies/ml who were at least 6 weeks postpartum. Sanger sequencing was used to detect resistant mutations, as well as host genotyping, and efavirenz resistance was compared among the metabolizer genotypes. Results: Over the course of one year (July 2017-July 2018), 322 women were screened, with 110 (34.2%) having viral loads of 1000 copies/ml and 62 having whole blood available for genotyping. Fifty-nine of these women had both viral resistance and human host genotypic results. Efavirenz resistance according to metabolizer genotype was; 47% in slow, 34% in extensive and 28% in intermediate metabolizers, but the difference was not statistically significant due to the small sample size. Conclusions: There was no statistically significant difference in EFV resistance between EFV metabolizer genotypes in women who started antiretroviral therapy during pregnancy and had high viremia in the postpartum period. However, a numerical trend was discovered, which calls for confirmation in a large, well-designed, statistically powered study. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF